BioSpace News Archive

Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced leadership updates.

Eyebiotech Limited (EyeBio), a clinical-stage ophthalmology biotechnology company, today announced the dosing of the first participants in its Phase 1b/2 AMARONE (Anti-permeability Mechanism and Age-Related Ocular Neovascularization Evaluation) clinical trial in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).

AIM ImmunoTech Inc. announced that Thomas K Equels, M.S., J.D., Executive Vice Chairman, Chief Executive Officer & President of AIM ImmunoTech, will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest on Wednesday, June 21, 2023 at 12:00 PM ET.

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 7th annual Immuno-Oncology Summit Europe which will take place June 20-22, 2023 in London, UK.

Cardiovascular health technology company, CardieX Limited, is pleased to announce it has been selected as part of MedTech Innovator’s 2023 Accelerator Cohort.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, shared new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate robust dose-dependent target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities observed.

Gilead Sciences, Inc. announced new data to be presented at the European Association for the Study of the Liver Congress 2023, June 21-24, 2023.

Royal Philips, a global leader in health technology, announced the results of a health economic analysis published in the Journal of NeuroInterventional Surgery that show an innovative approach to the stroke care pathway reduced costs by an average of EUR 2,848 per patient.

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that SWOG Cancer Research Network has joined the Caris Precision Oncology Alliance™.

Plus Therapeutics, Inc. announced that Marc Hedrick, M.D., President and Chief Executive Officer, has been invited to participate in a fireside chat at the 2023 Healthcare Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday, June 21, 2023 at 3:30 p.m. ET.